ORMP

NEW YORK (AP) — NEW YORK (AP) — Oramed Pharmaceuticals Inc. (ORMP) on Tuesday reported earnings of $38.3 million in its first quarter. The New York-based company said it had net income of 91 cents per share. Losses, adjusted for non-recurring gains, were 16 cents per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ORMP at https://www.zacks.com/ap/ORMP

NEW YORK (AP) — NEW YORK (AP) — Oramed Pharmaceuticals Inc. (ORMP) on Thursday reported profit of $10 million in its fourth quarter. The New York-based company said it had net income of 24 cents per share. Losses, adjusted for non-recurring gains, were 6 cents per share. For the year, the company reported profit of $64.1 million, or $1.50 per share. Revenue was reported as $2 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ORMP at https://www.zacks.com/ap/ORMP

On February 2, BML Capital Management disclosed in a Securities and Exchange Commission filing that it sold out of Alumis (NASDAQ:ALMS), liquidating 1,210,415 shares in an estimated $4.83 million trade. According to a Securities and Exchange Commission (SEC) filing dated February 2, BML Capital Management reported a complete sale of its 1,210,415-share stake in Alumis (NASDAQ:ALMS). As a result, the fund's quarter-end position value in Alumis decreased by $4.83 million, and it now holds no shares. Top holdings after the filing: NASDAQ: ACRS: $42.89 million (38.0% of AUM) NASDAQ: AVIR: $26.74 million (23.7% of AUM) NASDAQ: ORMP: $9.03 million (8.0% of AUM) NASDAQ: TIL: $7.10 million (6.3% of AUM) NASDAQ: PMVP: $6.62 million (5.9% of AUM) As of February 2, shares of Alumis were priced at $26.42, up a staggering 255.1% over the prior year and well outperforming the S&P 500’s roughly 15% gain in the same period. Alumis develops clinical-stage therapies for autoimmune and neuroinflammatory disorders, including ESK-001 and A-005 targeting TYK2 inhibition. The company operates a biopharmaceutical business model focused on advancing proprietary drug candidates through clinical trials toward regulatory approval and commercialization. It targets patients with autoimmune diseases such as plaque psoriasis, systemic lupus erythematosus, and neurodegenerative conditions. Alumis is a clinical-stage biotechnology company specializing in the development of novel therapies for autoimmune and neuroinflammatory diseases. The company leverages expertise in TYK2 inhibition to advance a pipeline of differentiated drug candidates addressing significant unmet medical needs. With a focus on innovation and clinical rigor, Alumis seeks to establish a competitive position in the biopharmaceutical sector through targeted therapeutic development. BML Capital’s move is a reminder that even disciplined portfolio decisions can collide with fast-moving catalysts. The sale was completed by December 31, as of the filing’s period-end date, before Alumis announced its January upsized public offering and before shares went on to surge roughly 200% in the weeks that followed. At the time, the decision was defensible. Alumis was a clinical-stage biotech with no approved products and heavy R&D spend. As of the third quarter, the company reported $377.7 million in cash and marketable securities, but a...

Investors appear disappointed with Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) recent earnings, despite the decent statutory profit number. We did some digging and found some worrying factors that they might be paying attention to. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'. Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". For the year to September 2025, Oramed Pharmaceuticals had an accrual ratio of 1.35. Statistically speaking, that's a real negative for future earnings. To wit, the company did not generate one whit of free cashflow in that time. Over the last year it actually had negative free cash flow of US$11m, in contrast to the aforementioned profit of US$43.9m. Coming off the back of negative free cash flow last year, we imagine some shareholders might wonder if its cash burn of US$11m, this year, indicates high risk. Having said that, there is more to the story. We can see that unusual items have impacted its statutory profit, and therefore the accrual ratio. View our latest analysis for Oramed Pharmaceuticals That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Given the accrual ratio, it's not overly surprising that Oramed Pharmaceuticals' profit was boosted by unusual items worth US$65m in the last twelve months. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies,...

Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025. Nine-Month Period 2025 Financial Highlights: Net income (pre-tax) of $65.0 million, compared to a net loss of $6.1 million in the same period last year Completed full repayment from Scilex: Received approximately $27 million during the period, bringing total repayment to $100 million and representing full return of principal from the Company's strategic investment Strong per-share performance: Basic earnings per share of $1.30; diluted earnings per share of $1.26 Robust balance sheet growth: Total assets increased 42% from $155.3 million to $220.5 million year-over-year Operating expenses: R&D expenses decreased from $4.9 million to $4.4 million; G&A expenses increased from $4.3 million to $5.0 million The significant improvement in net income was primarily driven by the combination of realized cash returns from Scilex Holding Company and substantial unrealized fair-value gains from the Company's equity holdings in Alpha Tau Medical Ltd. and other investments. Management Commentary Nadav Kidron, Chief Executive Officer of Oramed, commented: "Our disciplined investment strategy is delivering strong results. The complete $100 million cash repayment from Scilex, combined with substantial unrealized gains from our Alpha Tau position an other investments, has driven our $65 million net income and positioned us with greater financial flexibility to pursue strategic opportunities while advancing our oral drug delivery platform." About Oramed Pharmaceuticals Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Oramed's novel Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption. For more information, please visit www.oramed.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigatio...

NEW YORK (AP) — NEW YORK (AP) — Oramed Pharmaceuticals Inc. (ORMP) on Thursday reported net income of $48.4 million in its third quarter. The New York-based company said it had profit of $1.13 per share. Earnings, adjusted for non-recurring gains, were less than 1 cent on a per-share basis. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ORMP at https://www.zacks.com/ap/ORMP

NEW YORK (AP) — NEW YORK (AP) — Oramed Pharmaceuticals Inc. (ORMP) on Thursday reported net income of $13.3 million in its second quarter. On a per-share basis, the New York-based company said it had profit of 31 cents. Losses, adjusted for non-recurring gains, were 5 cents per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ORMP at https://www.zacks.com/ap/ORMP

NEW YORK (AP) — NEW YORK (AP) — Oramed Pharmaceuticals Inc. (ORMP) on Thursday reported a loss of $7.6 million in its first quarter. On a per-share basis, the New York-based company said it had a loss of 19 cents. The drug maker posted revenue of $2 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ORMP at https://www.zacks.com/ap/ORMP